News
-
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development
Innovative Molecules announces first patient dosed in Phase 2a trial of Adibelivir (IM-250), advancing company into late-stage clinical development